Abstract:Lung cancer is a significant cause of cancer-related death worldwide. It can be broadly categorised into small-cell lung cancer (SCLC) and Non-small cell lung cancer (NSCLC). Surgical intervention, radiation therapy, and the administration of chemotherapeutic medications are among the current treatment modalities. However, the application of chemotherapy may be limited in more advanced stages of metastasis due to the potential for adverse effects and a lack of cell selectivity. Although small-molecule anticancer treatments have demonstrated effectiveness, they still face several challenges. The challenges at hand in this context comprise insufficient solubility in water, limited bioavailability at specific sites, adverse effects, and the requirement for epidermal growth factor receptor inhibitors that are genetically tailored. Bio-macromolecular drugs, including small interfering RNA (siRNA) and messenger RNA (mRNA), are susceptible to degradation when exposed to the bodily fluids of humans, which can reduce stability and concentration. In this context, nanoscale delivery technologies are utilised. These agents offer encouraging prospects for the preservation and regulation of pharmaceutical substances, in addition to improving the solubility and stability of medications. Nanocarrier-based systems possess the notable advantage of facilitating accurate and sustained drug release, as opposed to traditional systemic methodologies. The primary focus of scientific investigation has been to augment the therapeutic efficacy of nanoparticles composed of lipids. Numerous nanoscale drug delivery techniques have been implemented to treat various respiratory ailments, such as lung cancer. These technologies have exhibited the potential to mitigate the limitations associated with conventional therapy. As an illustration, applying nanocarriers may enhance the solubility of small-molecule anticancer drugs and prevent the degradation of bio-macromolecular drugs. Furthermore, these devices can administer medications in a controlled and extended fashion, thereby augmenting the therapeutic intervention's effectiveness and reducing adverse reactions. However, despite these promising results, challenges remain that must be addressed. Multiple factors necessitate consideration when contemplating the application of nanoparticles in medical interventions. To begin with, the advancement of more efficient delivery methods is imperative. In addition, a comprehensive investigation into the potential toxicity of nanoparticles is required. Finally, additional research is needed to comprehend these treatments' enduring ramifications. Despite these challenges, the field of nanomedicine demonstrates considerable promise in enhancing the therapy of lung cancer and other respiratory diseases.

Fullerene-based nanocomplex assists pulmonary delivery of siRNA for treating metastatic lung cancer

A Nanoplatform Self-Assembled by Coordination Delivers Sirna for Lung Cancer Therapy

A pH sensitive co-delivery system of siRNA and doxorubicin for pulmonary administration to B16F10 metastatic lung cancer

A Two‐Pronged Pulmonary Gene Delivery Strategy: A Surface‐Modified Fullerene Nanoparticle and a Hypotonic Vehicle

Biomembrane-derived nanoplexes for SiRNAs-pioneer innovation in delivery to lung adenocarcinoma

Inter-molecular β-sheet structure facilitates lung-targeting siRNA delivery

Nanoparticle‐Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis

Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG 12 -KL4 peptide to the lungs as potential strategy against non-small cell lung cancer

Efficient Systemic Delivery Of Sirna By Using High-Density Lipoprotein-Mimicking Peptide Lipid Nanoparticles

Codelivery of CPT and siPHB1 with GSH/ROS Dual-Responsive Hybrid Nanoparticles Based on a [12]aneN3-Derived Lipid for Synergistic Lung Cancer Therapy

The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy

Enhanced Antitumor Efficacies of Multifunctional Nanocomplexes Through Knocking Down the Barriers for Sirna Delivery

Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection

A novel platform to enable inhaled naked RNAi medicine for lung cancer

In Vivo Self-Assembly and Delivery of VEGFR2 Sirna-Encapsulated Small Extracellular Vesicles for Lung Metastatic Osteosarcoma Therapy.

Lipid-Based Nanocarriers for Targeted Gene Delivery in Lung Cancer Therapy: Exploring a Novel Therapeutic Paradigm

Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy

Smart Nanoparticles Assembled by Endogenous Molecules for Sirna Delivery and Cancer Therapy Via CD44 and EGFR Dual-Targeting

Binary and Ternary Complexes Based on Polycaprolactone-Graft-Poly (N, N-Dimethylaminoethyl Methacrylate) for Targeted Sirna Delivery

Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer

Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery